Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.

Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2019 Nov 28:1-12. doi: 10.1080/10428194.2019.1695051. [Epub ahead of print]

PMID:
31779510
2.

Data Logging Evidence of Cochlear Implant Use in Single-Sided and Bilateral Deafness.

Rauch AK, Kagermann S, Wesarg T, Jakob TF, Aschendorff A, Ihorst G, Speck I, Arndt S.

Audiol Neurootol. 2019;24(4):206-216. doi: 10.1159/000502051. Epub 2019 Sep 11.

PMID:
31509836
3.

TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis.

Pantic M, Pfeifer D, Kapp-Schwoerer S, Ihorst G, Becker H, Zeiser R, Duyster J, Schmitt-Graeff A.

Leukemia. 2019 Dec;33(12):2956-2962. doi: 10.1038/s41375-019-0523-8. Epub 2019 Jul 26. No abstract available.

PMID:
31350530
5.

Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.

Schorb E, Finke J, Ihorst G, Kasenda B, Fricker H, Illerhaus G.

BMC Cancer. 2019 Mar 29;19(1):287. doi: 10.1186/s12885-019-5473-z.

6.

Dynamic prediction: A challenge for biostatisticians, but greatly needed by patients, physicians and the public.

Schumacher M, Hieke S, Ihorst G, Engelhardt M.

Biom J. 2019 Mar 25. doi: 10.1002/bimj.201800248. [Epub ahead of print]

PMID:
30908745
7.

High-resolution contrast-enhanced vessel wall imaging in patients with suspected cerebral vasculitis: Prospective comparison of whole-brain 3D T1 SPACE versus 2D T1 black blood MRI at 3 Tesla.

Eiden S, Beck C, Venhoff N, Elsheikh S, Ihorst G, Urbach H, Meckel S.

PLoS One. 2019 Mar 8;14(3):e0213514. doi: 10.1371/journal.pone.0213514. eCollection 2019.

8.

Correction: ComOn-Coaching: The effect of a varied number of coaching sessions on transfer into clinical practice following communication skills training in oncology: Results of a randomized controlled trial.

Niglio de Figueiredo M, Krippeit L, Ihorst G, Sattel H, Bylund CL, Joos A, Bengel J, Lahmann C, Fritzsche K, Wuensch A.

PLoS One. 2019 Jan 29;14(1):e0211752. doi: 10.1371/journal.pone.0211752. eCollection 2019.

9.
10.

APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells.

Ewerth D, Kreutmair S, Schmidts A, Ihorst G, Follo M, Wider D, Felthaus J, Schüler J, Duyster J, Illert AL, Engelhardt M, Wäsch R.

Cell Mol Life Sci. 2019 Jan;76(2):369-380. doi: 10.1007/s00018-018-2952-3. Epub 2018 Oct 24.

PMID:
30357422
11.

Regeneration of older patients after oncologic surgery. A temporal trajectory of geriatric assessment and quality of life parameters.

Deschler B, Ihorst G, Hüll M, Baier P.

J Geriatr Oncol. 2019 Jan;10(1):112-119. doi: 10.1016/j.jgo.2018.09.010. Epub 2018 Oct 9.

PMID:
30314954
12.

ComOn-Coaching: The effect of a varied number of coaching sessions on transfer into clinical practice following communication skills training in oncology: Results of a randomized controlled trial.

Niglio de Figueiredo M, Krippeit L, Ihorst G, Sattel H, Bylund CL, Joos A, Bengel J, Lahmann C, Fritzsche K, Wuensch A.

PLoS One. 2018 Oct 5;13(10):e0205315. doi: 10.1371/journal.pone.0205315. eCollection 2018. Erratum in: PLoS One. 2019 Jan 29;14(1):e0211752.

13.

The Memorial Sloan Kettering Cancer Center Nomogram is More Accurate than the 2009 FIGO Staging System in the Prediction of Overall Survival in a German Endometrial Cancer Patient Cohort.

Huss A, Ihorst G, Timme-Bronsert S, Hasenburg A, Oehler MK, Klar M.

Ann Surg Oncol. 2018 Dec;25(13):3966-3973. doi: 10.1245/s10434-018-6756-3. Epub 2018 Sep 20.

PMID:
30238246
14.

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R.

Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.

15.

Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.

Stomper J, Ihorst G, Suciu S, Sander PN, Becker H, Wijermans PW, Plass C, Weichenhan D, Bissé E, Claus R, Lübbert M.

Haematologica. 2019 Jan;104(1):59-69. doi: 10.3324/haematol.2017.187278. Epub 2018 Aug 31.

16.

GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.

Schmidts A, Grünewald J, Kleber M, Terpos E, Ihorst G, Reinhardt H, Walz G, Wäsch R, Engelhardt M, Zschiedrich S.

Clin Exp Nephrol. 2019 Feb;23(2):199-206. doi: 10.1007/s10157-018-1626-7. Epub 2018 Aug 20.

PMID:
30128942
17.

Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning.

Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, Müller-Quernheim J, Finke J, Marks R, Prasse A.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2277-2284. doi: 10.1016/j.bbmt.2018.06.024. Epub 2018 Jun 28.

18.

Rejection Prophylaxis in Corneal Transplant.

Böhringer D, Grotejohann B, Ihorst G, Reinshagen H, Spierings E, Reinhard T.

Dtsch Arztebl Int. 2018 Apr 13;115(15):259-265. doi: 10.3238/arztebl.2018.0259.

19.

Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.

Engelhardt M, Herget GW, Graziani G, Ihorst G, Reinhardt H, Ajayi S, Knop S, Wasch R.

Haematologica. 2018 May;103(5):755-758. doi: 10.3324/haematol.2018.188516. No abstract available.

20.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M.

Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19. No abstract available.

21.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
22.

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials<sup/>.

Gengenbach L, Reinhardt H, Ihorst G, Ajayi S, Dold SM, Köhler M, Einsele H, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2018 Nov;59(11):2692-2699. doi: 10.1080/10428194.2018.1448084. Epub 2018 Mar 23. No abstract available.

PMID:
29569975
23.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

24.

Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis.

Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J.

Bone Marrow Transplant. 2018 May;53(5):565-575. doi: 10.1038/s41409-017-0021-4. Epub 2018 Jan 12.

PMID:
29330399
25.

Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.

Greil C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, Kühbach K, Bosse R, Duyster J, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2018 Jul;59(7):1722-1725. doi: 10.1080/10428194.2017.1393673. Epub 2017 Oct 30. No abstract available.

PMID:
29081261
26.

Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study.

Naegele M, Kirsch M, Ihorst G, Fierz K, Engelhardt M, De Geest S.

Support Care Cancer. 2018 Mar;26(3):833-841. doi: 10.1007/s00520-017-3897-z. Epub 2017 Sep 16.

PMID:
28918604
27.

The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.

Greil C, Ihorst G, Gaiser F, Salzer U, Bisse E, Kastritis E, Ludwig H, Wäsch R, Engelhardt M.

Eur J Haematol. 2017 Nov;99(5):449-458. doi: 10.1111/ejh.12958. Epub 2017 Oct 5.

PMID:
28886228
28.

Assessing Communication Skills in Real Medical Encounters in Oncology: Development and Validation of the ComOn-Coaching Rating Scales.

Niglio de Figueiredo M, Krippeit L, Freund J, Ihorst G, Joos A, Bengel J, Wuensch A.

J Cancer Educ. 2019 Feb;34(1):73-81. doi: 10.1007/s13187-017-1269-5.

PMID:
28815515
29.

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.

Br J Haematol. 2017 Oct;179(1):36-49. doi: 10.1111/bjh.14807. Epub 2017 Jul 2.

PMID:
28670693
30.

Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.

Strüßmann T, Fritsch K, Baumgarten A, Fietz T, Engelhardt M, Mertelsmann R, Ihorst G, Duyster J, Finke J, Marks R.

Br J Haematol. 2017 Sep;178(6):927-935. doi: 10.1111/bjh.14802. Epub 2017 Jun 23.

PMID:
28643323
31.

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.

Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G.

Leukemia. 2017 Dec;31(12):2623-2629. doi: 10.1038/leu.2017.170. Epub 2017 May 31.

PMID:
28559537
32.

Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression.

Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R.

Oncotarget. 2017 Jun 27;8(26):42901-42916. doi: 10.18632/oncotarget.17160.

33.

Effect of individualized communication skills training on physicians' discussion of clinical trials in oncology: results from a randomized controlled trial.

Wuensch A, Goelz T, Ihorst G, Terris DD, Bertz H, Bengel J, Wirsching M, Fritzsche K.

BMC Cancer. 2017 Apr 13;17(1):264. doi: 10.1186/s12885-017-3238-0.

34.

[Multidisciplinary Tumor Boards: Facts and Satisfaction Analysis of an Indispensable Comprehensive Cancer Center Instrument].

Engelhardt M, Selder R, Pandurevic M, Möller M, Ihorst G, Waldschmidt J, Herget G, Wäsch R.

Dtsch Med Wochenschr. 2017 May;142(9):e51-e60. doi: 10.1055/s-0043-100054. Epub 2017 Feb 27. German.

PMID:
28241373
35.

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.

Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, Müller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, Wäsch R.

Haematologica. 2017 May;102(5):910-921. doi: 10.3324/haematol.2016.162693. Epub 2017 Feb 2.

36.

Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.

Greil C, Kiote-Schmidt C, Fink G, Ihorst G, Hildenbeutel S, Bosse R, Duyster J, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2017 Aug;58(8):1849-1858. doi: 10.1080/10428194.2016.1271946. Epub 2017 Jan 13.

PMID:
28084849
37.

Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).

Lübbert M, Ihorst G, Sander PN, Bogatyreva L, Becker H, Wijermans PW, Suciu S, Bissé E, Claus R.

Br J Haematol. 2017 Feb;176(4):609-617. doi: 10.1111/bjh.14463. Epub 2016 Dec 1.

PMID:
27905102
38.

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).

Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G.

Leukemia. 2017 Apr;31(4):846-852. doi: 10.1038/leu.2016.334. Epub 2016 Nov 15.

39.

Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?

Engelhardt M, Ihorst G, Caers J, Günther A, Wäsch R.

Haematologica. 2016 Nov;101(11):1276-1278. No abstract available.

40.

Independence and health related quality of life in 200 onco-geriatric surgical patients within 6 months of follow-up: Who is at risk to lose?

Baier P, Ihorst G, Wolff-Vorbeck G, Hüll M, Hopt U, Deschler B.

Eur J Surg Oncol. 2016 Dec;42(12):1890-1897. doi: 10.1016/j.ejso.2016.07.013. Epub 2016 Jul 30.

PMID:
27519617
41.

Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.

Engelhardt M, Dold SM, Ihorst G, Zober A, Möller M, Reinhardt H, Hieke S, Schumacher M, Wäsch R.

Haematologica. 2016 Sep;101(9):1110-9. doi: 10.3324/haematol.2016.148189. Epub 2016 Jun 16.

42.

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.

Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J.

Lancet Haematol. 2016 Aug;3(8):e388-97. doi: 10.1016/S2352-3026(16)30050-3. Epub 2016 Jul 13.

PMID:
27476790
43.

High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).

Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G.

BMC Cancer. 2016 Apr 21;16:282. doi: 10.1186/s12885-016-2311-4.

44.

High Rates of Thromboembolic Events in Patients with Germ Cell Cancer Undergoing Cisplatin-Based Polychemotherapy.

Solari L, Krönig M, Ihorst G, Drognitz K, Heinz J, Jilg CA, Schultze-Seemann W, Engelhardt M, Waller CF.

Urol Int. 2016;96(4):399-405. doi: 10.1159/000445126. Epub 2016 Apr 14.

PMID:
27074038
45.

Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.

Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich SP, Joachimsen L, Rauer S, Pielen A, Sühs KW, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Tonagel F, Kernstock C, Hartmann K, Kümpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Müller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagrèze WA.

BMJ Open. 2016 Mar 1;6(3):e010956. doi: 10.1136/bmjopen-2015-010956.

46.

Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.

Chevalier N, Mueller M, Mougiakakos D, Ihorst G, Marks R, Schmitt-Graeff A, Veelken H.

Leuk Lymphoma. 2016 Sep;57(9):2150-60. doi: 10.3109/10428194.2015.1135432. Epub 2016 Jan 12. Erratum in: Leuk Lymphoma. 2016 Sep;57(9):I.

PMID:
26757600
47.

Endovascular Cooling Catheter for Selective Brain Hypothermia: An Animal Feasibility Study of Cooling Performance.

Cattaneo G, Schumacher M, Maurer C, Wolfertz J, Jost T, Büchert M, Keuler A, Boos L, Shah MJ, Foerster K, Niesen WD, Ihorst G, Urbach H, Meckel S.

AJNR Am J Neuroradiol. 2016 May;37(5):885-91. doi: 10.3174/ajnr.A4625. Epub 2015 Dec 24.

48.

Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.

Philipsen A, Jans T, Graf E, Matthies S, Borel P, Colla M, Gentschow L, Langner D, Jacob C, Groß-Lesch S, Sobanski E, Alm B, Schumacher-Stien M, Roesler M, Retz W, Retz-Junginger P, Kis B, Abdel-Hamid M, Heinrich V, Huss M, Kornmann C, Bürger A, Perlov E, Ihorst G, Schlander M, Berger M, Tebartz van Elst L; Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS) Consortium.

JAMA Psychiatry. 2015 Dec;72(12):1199-210. doi: 10.1001/jamapsychiatry.2015.2146. Erratum in: JAMA Psychiatry. 2016 Jan;73(1):90.

PMID:
26536057
49.

From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.

Lorenz J, Waldschmidt J, Wider D, Follo M, Ihorst G, Chatterjee M, May AM, Duyster J, Rosenwald A, Wäsch R, Zirlik K, Engelhardt M.

Br J Haematol. 2016 Sep;174(6):985-9. doi: 10.1111/bjh.13825. Epub 2015 Oct 22. No abstract available.

PMID:
26491948
50.

The impact of pre-transplant body weight on short- and long-term outcomes after allogeneic hematopoietic cell transplantation in adults using different weight classification tools.

Urbain P, Ihorst G, Finke J, Bertz H.

Bone Marrow Transplant. 2016 Jan;51(1):144-7. doi: 10.1038/bmt.2015.219. Epub 2015 Oct 5. No abstract available.

PMID:
26437059

Supplemental Content

Loading ...
Support Center